Search

Your search keyword '"Suvisaari, Janne"' showing total 24 results
Start Over Author "Suvisaari, Janne"
24 results on '"Suvisaari, Janne"'

2. The multidimensional value of natriuretic peptides in heart failure, integrating laboratory and clinical aspects.

Author

Gruson, Damien, Hammerer-Lercher, Angelika, Collinson, Paul, Duff, Christopher, Baum, Hannsjörg, Pulkki, Kari, Suvisaari, Janne, Stankovic, Sanja, Laitinen, Paivi, and Bayes-Genis, Antoni

Subjects
HEART failure risk factors, RISK assessment, PATIENT education, SELF-efficacy, HEART failure, PEPTIDE hormones, EARLY diagnosis, DYSPNEA, NATRIURETIC peptides, BIOMARKERS, SYMPTOMS
Abstract

Natriuretic peptides (NP) play an essential role in heart failure (HF) regulation, and their measurement has improved diagnostic and prognostic accuracy. Clinical symptoms and objective measurements, such as NP levels, should be included in the HF definition to render it more reliable and consistent among observers, hospitals, and healthcare systems. BNP and NT-proBNP are reasonable surrogates for cardiac disease, and their measurement is critical to early diagnosis and risk stratification of HF patients. NPs should be measured in all patients presenting with dyspnea or other symptoms suggestive of HF to facilitate early diagnosis and risk stratification. Both BNP and NT-proBNP are currently used for guided HF management and display comparable diagnostic and prognostic accuracy. Standardized cutoffs for each NP assay are essential for data comparison. The value of NP testing is recognized at various levels, including patient empowerment and education, analytical and operational issues, clinical HF management, and cost-effectiveness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Changing Immunochemistry Platforms: Thyroid Function Test Comparison and Reference Intervals Based on Clinical Needs .

Author

Pelanti, Jonna, Lamberg, Tea, Salopuro, Titta, Pussinen, Christel, Suvisaari, Janne, Joutsi-Korhonen, Lotta, Schalin-Jäntti, Camilla, Itkonen, Outi, and Anttonen, Mikko

Subjects
IMMUNOCHEMISTRY, THYROTROPIN, THYROID diseases, THYROID hormones, IMMUNOASSAY, THYROID gland function tests, THYROID hormone regulation
Abstract

Background: Diagnosis of thyroid dysfunction relies on thyroid stimulating hormone (TSH), free thyroxine (FT4), and free tri-iodothyronine (FT3) tests against valid reference intervals (RIs). We changed the immunoassay platform from Abbott Architect to Siemens Atellica and aimed to establish Atellica RIs based on laboratory information system (LIS) patient data. Methods: Atellica thyroid hormone immunoassays were verified against those of Architect. Real-life patient results were retrieved from LIS. A single result per patient dataset was used to establish the RIs by the indirect method. Results: Atellica and Architect assays correlated well but Atellica showed a positive bias between 13% and 53%, the largest for FT4. Variations of the Atellica assays were ≤4%. The 95% Atellica RIs were 0.4–3.8 mU/L for TSH, 0.9–1.6 ng/dL for FT4, and 227–416 pg/dL for FT3. Considering the accumulating clinical experience with Atellica, the RIs for clinical use were adjusted as 0.5–4.0 mU/L, 0.9–1.8 ng/dL, and 169–409 pg/dL, respectively. Conclusions: We verified thyroid hormone RIs for Atellica by the indirect method for the first time. Our model proved reliable for selecting results of presumably healthy individuals from LIS data. Critical review of the RIs with local endocrinologists is essential. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. How Well Do Laboratories Adhere to Recommended Guidelines for Cardiac Biomarkers Management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) Study of the European Federation of Laboratory Medicine Task Group on Cardiac Markers.

Author

Collinson, Paul, Suvisaari, Janne, Aakre, Kristin M., Baum, Hannsjörg, Duff, Christopher J., Gruson, Damien, Hammerer-Lercher, Angelika, Pulkki, Kari, Stankovic, Sanja, Langlois, Michel R., and Apple, Fred S.

Published
2021
Full Text
View/download PDF

13. Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study

Author

Hammerer-Lercher, Angelika, primary, Collinson, Paul O., additional, Suvisaari, Janne, additional, Christenson, Robert H., additional, Pulkki, Kari, additional, van Dieijen-Visser, Marja P., additional, Duff, Christopher J., additional, Baum, Hannsjörg, additional, Stavljenic-Rukavina, Ana, additional, Aakre, Kristin M., additional, Langlois, Michel R., additional, Stankovic, Sanja, additional, and Laitinen, Paivi, additional

Published
2017
Full Text
View/download PDF

14. How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE)

Author

Collinson, Paul, primary, Hammerer-Lercher, Angelika, primary, Suvisaari, Janne, primary, Apple, Fred S, primary, Christenson, Rob H, primary, Pulkki, Kari, primary, van Dieijen-Visser, Marja P, primary, Duff, Christopher J, primary, Baum, Hannsjörg, primary, Stavljenic-Rukavina, Ana, primary, Aakre, Kristin M, primary, Langlois, Michel R, primary, Stankovic, Sanja, primary, and Laitinen, Paivi, primary

Published
2016
Full Text
View/download PDF

15. Evidence-Based Laboratory Medicine: HowWell Do Laboratories Follow Recommendations and Guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study

Author

Collinson, Paul, van Dieijen-Visser, Marja, Pulkk, Kari, Hammerer-Lercher, Angelika, Suvisaari, Janne, Ravkilde, Jan, Stavljenic- Rukavina, Ana, Baum, Hansjorg, and LaitinenPaivi

Subjects
evidence based, laboratorymedicine, cardiac marker guidelines
Abstract

The original Cardiac MarkerGuideline Uptake in Europe (CARMAGUE) study (1 ) surveyed laboratory practice against the then current clinical practice recommendations.Responses were obtained from 303 laboratories in 28 countries.The responders were from a full range of laboratories: 34% universityhospital laboratories, 36% districthospitals, 25% central hospitals, and 5% primary care acilities.Ninety-five percent of the laboratories used troponin as the preferred marker for routine diagnosis of suspected acute coronary syndromes.Fifty percent of the laboratories use troponin T, and 45% used troponin I.Thirty-one percent of the laboratories used troponin as the sole marker, but 69% combined troponin measurement with another marker and offered other marker tests in suspected cases of acute coronary syndrom.The wide range of choice of decision limits may in part represent laboratory conservatism, physician resistance, or a feeling that assay performance is inadequate for using a 99th percentile value. There is a need for independent validation of both assay performance and 99th percentile values to provide decision limits for MI independent of manufacturers’.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results